Clinical Trials Logo

Relapse Multiple Myeloma clinical trials

View clinical trials related to Relapse Multiple Myeloma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04918511 Withdrawn - Multiple Myeloma Clinical Trials

A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma

COAST
Start date: May 27, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of a single infusion of OPD5 before Autologous Stem Cell Transplant in patients with RRMM. The study will evaluate increasing doses of OPD5 to find the best dose and to assess any side effects. Each patient will be assigned to a dose cohort of 3-6 patients to receive one single dose of OPD5. Each patient will be hospitalized for about 14 days from the OPD5 infusion and then have monthly visits to the clinic for 3 months and then every third month until disease progression or starting new myeloma treatment, maximum up to 2 years.

NCT ID: NCT04355039 Withdrawn - Clinical trials for Refractory Multiple Myeloma

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

This is a prospective, single-center, open-label phase Ib study aimed at determining a recommended phase II dose of INCB053914 and pomalidomide with dexamethasone. The trial will follow a 3 + 3 phase I dose-escalation design.